QQQ   423.19 (-0.62%)
AAPL   166.91 (-0.65%)
MSFT   405.39 (-1.57%)
META   501.50 (+1.48%)
GOOGL   156.22 (+0.48%)
AMZN   179.00 (-1.26%)
TSLA   150.48 (-3.20%)
NVDA   844.72 (+0.52%)
AMD   154.17 (+0.10%)
NIO   4.02 (+2.81%)
BABA   68.88 (+0.09%)
T   16.23 (+0.68%)
F   12.01 (-0.25%)
MU   112.61 (-3.20%)
GE   153.90 (-1.14%)
CGC   8.12 (+25.12%)
DIS   112.83 (-0.10%)
AMC   2.92 (-2.01%)
PFE   25.33 (-0.35%)
PYPL   62.22 (-1.64%)
XOM   118.24 (-0.33%)
QQQ   423.19 (-0.62%)
AAPL   166.91 (-0.65%)
MSFT   405.39 (-1.57%)
META   501.50 (+1.48%)
GOOGL   156.22 (+0.48%)
AMZN   179.00 (-1.26%)
TSLA   150.48 (-3.20%)
NVDA   844.72 (+0.52%)
AMD   154.17 (+0.10%)
NIO   4.02 (+2.81%)
BABA   68.88 (+0.09%)
T   16.23 (+0.68%)
F   12.01 (-0.25%)
MU   112.61 (-3.20%)
GE   153.90 (-1.14%)
CGC   8.12 (+25.12%)
DIS   112.83 (-0.10%)
AMC   2.92 (-2.01%)
PFE   25.33 (-0.35%)
PYPL   62.22 (-1.64%)
XOM   118.24 (-0.33%)
QQQ   423.19 (-0.62%)
AAPL   166.91 (-0.65%)
MSFT   405.39 (-1.57%)
META   501.50 (+1.48%)
GOOGL   156.22 (+0.48%)
AMZN   179.00 (-1.26%)
TSLA   150.48 (-3.20%)
NVDA   844.72 (+0.52%)
AMD   154.17 (+0.10%)
NIO   4.02 (+2.81%)
BABA   68.88 (+0.09%)
T   16.23 (+0.68%)
F   12.01 (-0.25%)
MU   112.61 (-3.20%)
GE   153.90 (-1.14%)
CGC   8.12 (+25.12%)
DIS   112.83 (-0.10%)
AMC   2.92 (-2.01%)
PFE   25.33 (-0.35%)
PYPL   62.22 (-1.64%)
XOM   118.24 (-0.33%)
QQQ   423.19 (-0.62%)
AAPL   166.91 (-0.65%)
MSFT   405.39 (-1.57%)
META   501.50 (+1.48%)
GOOGL   156.22 (+0.48%)
AMZN   179.00 (-1.26%)
TSLA   150.48 (-3.20%)
NVDA   844.72 (+0.52%)
AMD   154.17 (+0.10%)
NIO   4.02 (+2.81%)
BABA   68.88 (+0.09%)
T   16.23 (+0.68%)
F   12.01 (-0.25%)
MU   112.61 (-3.20%)
GE   153.90 (-1.14%)
CGC   8.12 (+25.12%)
DIS   112.83 (-0.10%)
AMC   2.92 (-2.01%)
PFE   25.33 (-0.35%)
PYPL   62.22 (-1.64%)
XOM   118.24 (-0.33%)
Free Trial

Compare Stocks

→ Nvidia Has a BIG Problem — Here’s Who Benefits MOST (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atlanta Gold Inc stock logo
ATG
Atlanta Gold
C$0.03
+∞		C$0.03
C$0.03
▼
C$0.06
C$2.28MN/A55,868 shs3,200 shs
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
$7.81
$7.81
$4.06
▼
$9.16
N/AN/AN/AN/A
These 7 Stocks Will Be Magnificent in 2024 Cover
These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atlanta Gold Inc stock logo
ATG
Atlanta Gold
0.00%0.00%0.00%0.00%0.00%
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atlanta Gold Inc stock logo
ATG
Atlanta Gold
N/AN/AN/AN/AN/AN/AN/AN/A
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atlanta Gold Inc stock logo
ATG
Atlanta Gold
N/AN/AN/AN/A
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atlanta Gold Inc stock logo
ATG
Atlanta Gold
N/AN/AN/AN/AC$0.39 per shareN/A
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atlanta Gold Inc stock logo
ATG
Atlanta Gold
N/A-C$0.02N/A∞N/AN/AN/AN/AN/A
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
N/AN/A0.00∞N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atlanta Gold Inc stock logo
ATG
Atlanta Gold
N/AN/AN/AN/AN/A
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atlanta Gold Inc stock logo
ATG
Atlanta Gold
31.94
0.00
N/A
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Atlanta Gold Inc stock logo
ATG
Atlanta Gold
N/A
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
N/A

Insider Ownership

CompanyInsider Ownership
Atlanta Gold Inc stock logo
ATG
Atlanta Gold
N/A
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
72.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Atlanta Gold Inc stock logo
ATG
Atlanta Gold
N/A76.15 millionN/ANot Optionable
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
6N/AN/ANot Optionable

MONY, CNIC, ATG, and EMIS Headlines

SourceHeadline
Global Microbial Therapeutic Products Industry Is Expected to Reach US$30.55 Billion at a 7.5% CAGR by 2030 | FMIGlobal Microbial Therapeutic Products Industry Is Expected to Reach US$30.55 Billion at a 7.5% CAGR by 2030 | FMI
fmiblog.com - April 9 at 2:00 PM
Exco Technologies Limited (XTC.TO)Exco Technologies Limited (XTC.TO)
ca.finance.yahoo.com - March 3 at 2:53 PM
Global Microbial Therapeutic Products Industry Poised for 7.5% CAGR, Eyeing US$ 30.55 Billion Valuation by 2030 | FMI InsightsGlobal Microbial Therapeutic Products Industry Poised for 7.5% CAGR, Eyeing US$ 30.55 Billion Valuation by 2030 | FMI Insights
pharmiweb.com - December 21 at 2:04 PM
Insulin pill could free diabetics from jabsInsulin pill could free diabetics from jabs
dailymail.co.uk - December 11 at 8:35 AM
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Emisphere Technologies, Inc. with Losses of $100,000 to Contact the FirmSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Emisphere Technologies, Inc. with Losses of $100,000 to Contact the Firm
barrons.com - November 19 at 2:57 PM
Global Microbial Therapeutic Products Industry to Surpass US$ 30 Billion by 2030, Exhibiting 7.5% Growth | FMI ReportGlobal Microbial Therapeutic Products Industry to Surpass US$ 30 Billion by 2030, Exhibiting 7.5% Growth | FMI Report
pharmiweb.com - November 8 at 3:16 PM
EMIS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Emisphere Technologies, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!EMIS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Emisphere Technologies, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
businesswire.com - October 23 at 8:34 PM
Class Action Complaint Filed Against Emisphere Technologies, Inc.Class Action Complaint Filed Against Emisphere Technologies, Inc.
jdjournal.com - October 6 at 1:06 PM
Entwistle & Cappucci LLP Files a Securities Class Action Complaint Against Emisphere Technologies, Inc.Entwistle & Cappucci LLP Files a Securities Class Action Complaint Against Emisphere Technologies, Inc.
benzinga.com - October 5 at 8:24 PM
Microbial Therapeutic Products Market Anticipates 7.5% CAGR, Envisioning a US$ 30.55 Billion Industry by 2030 | FMIMicrobial Therapeutic Products Market Anticipates 7.5% CAGR, Envisioning a US$ 30.55 Billion Industry by 2030 | FMI
pharmiweb.com - August 25 at 4:56 PM
Lionsgate Chairman Rachesky Loses Bid to End Emisphere Deal CaseLionsgate Chairman Rachesky Loses Bid to End Emisphere Deal Case
news.bloomberglaw.com - August 3 at 8:53 PM
Microbial Therapeutic Products Market is projected to register 7.5% CAGR and reach a valuation of US$ 30.55 Billion by of 2030Microbial Therapeutic Products Market is projected to register 7.5% CAGR and reach a valuation of US$ 30.55 Billion by of 2030
fmiblog.com - June 12 at 3:04 PM
Buccal Drug Delivery System Global Market Report 2023Buccal Drug Delivery System Global Market Report 2023
finance.yahoo.com - May 8 at 12:41 PM
Flying high on obesity success, Novos appetite for partnerships growsFlying high on obesity success, Novo's appetite for partnerships grows
health.economictimes.indiatimes.com - May 5 at 5:15 AM
Flying high on obesity success, Novos appetite for deals growsFlying high on obesity success, Novo's appetite for deals grows
msn.com - May 4 at 1:37 PM
Informative Market Research Report on Thrombin Inhibitor with Estimated CAGR of 12.5% from 2023-2030Informative Market Research Report on Thrombin Inhibitor with Estimated CAGR of 12.5% from 2023-2030
marketwatch.com - April 16 at 8:50 AM
Microbial Therapeutic Products Market is anticipated to attain a valuation of US$ 30.55 Billion by 2030 at a high CAGR of 7.5%Microbial Therapeutic Products Market is anticipated to attain a valuation of US$ 30.55 Billion by 2030 at a high CAGR of 7.5%
fmiblog.com - April 14 at 3:19 AM
Oral Biologics & Biosimilars Global Market Report 2023Oral Biologics & Biosimilars Global Market Report 2023
uk.finance.yahoo.com - April 11 at 2:26 PM
Incretin-Based Drugs Market Size Regional Analysis 2023 which includes Rapid Growth Rate Till 2025Incretin-Based Drugs Market Size Regional Analysis 2023 which includes Rapid Growth Rate Till 2025
marketwatch.com - March 2 at 7:39 AM
Global Non-insulin Diabetes Therapeutics Market Size Analysis, Share, Application, Opportunities Forecast to 2030 By VMReportsGlobal Non-insulin Diabetes Therapeutics Market Size Analysis, Share, Application, Opportunities Forecast to 2030 By VMReports
marketwatch.com - February 19 at 10:18 AM
Insulin Detemir Market 2023 Size, Share, Applications, Advance Technology And Top Companies To 2026Insulin Detemir Market 2023 Size, Share, Applications, Advance Technology And Top Companies To 2026
marketwatch.com - February 14 at 6:15 PM
Microbial Therapeutic Products Market Future Scenarios, Growth and Analytical Insights – 2030Microbial Therapeutic Products Market Future Scenarios, Growth and Analytical Insights – 2030
fmiblog.com - September 26 at 3:59 PM
Global Pernicious Anemia Market Report 2022-2028: Increasing Prevalence of Autoimmune Conditions Driving Sector Growth - ResearchAndMarkets.comGlobal Pernicious Anemia Market Report 2022-2028: Increasing Prevalence of Autoimmune Conditions Driving Sector Growth - ResearchAndMarkets.com
finance.dailyherald.com - September 26 at 10:58 AM
Oral Biologics & Biosimilars Global Market Report 2022Oral Biologics & Biosimilars Global Market Report 2022
benzinga.com - September 23 at 1:28 PM

Media Sentiment Over Time

Company Descriptions

Atlanta Gold logo

Atlanta Gold

CVE:ATG
Atlanta Gold Inc. operates as a junior gold exploration and development company in the United States. Its principal property is the Atlanta gold property that covers an area of 2,159 acres located in Idaho. The company was formerly known as Twin Mining Corporation and changed its name to Atlanta Gold Inc. in March 2007. Atlanta Gold Inc. was founded in 1985 and is headquartered in Toronto, Canada.
Emisphere Technologies logo

Emisphere Technologies

OTCMKTS:EMIS
Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.